Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Heron Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies to address unmet needs in acute care, particularly in oncology supportive care and postoperative pain management. The company’s commercial portfolio targets hospital and surgical settings, with products designed to improve patient outcomes and reduce reliance on opioids and other legacy standards of care. Heron operates as a single-reportable biopharmaceutical segment and generates revenue primarily from product sales in the United States.
Heron’s key marketed products include CINVANTI® (aprepitant injectable emulsion) for chemotherapy‑induced nausea and vomiting (CINV), ZYNRELEF® (bupivacaine and meloxicam extended‑release) for postsurgical pain, and APONVIE® (aprepitant injectable emulsion) for postoperative nausea and vomiting (PONV). The company’s strategic positioning centers on proprietary drug formulation technologies that enable extended‑release local delivery and IV administration without traditional solvents. Heron was originally founded in 1983 and later rebranded as Heron Therapeutics in 2012 as it shifted its focus toward oncology supportive care and acute pain therapeutics.
Business Operations
Heron Therapeutics conducts its operations primarily through integrated research, clinical development, regulatory, and commercial functions within the United States. The company generates revenue through the commercialization of its FDA‑approved products, which are sold mainly to hospitals, ambulatory surgery centers, and oncology clinics. Manufacturing is largely outsourced to third‑party contract manufacturers, while Heron retains control over formulation technology, regulatory strategy, and commercialization.
The company’s core assets are based on proprietary polymer‑based drug delivery platforms that enable sustained local release or IV administration of poorly soluble compounds. Heron markets its products through a dedicated U.S. hospital‑focused sales organization and maintains distribution relationships with major pharmaceutical wholesalers. Public disclosures do not indicate material revenue‑generating joint ventures; collaboration activity has primarily supported manufacturing, supply chain, and limited regional distribution outside the United States.
Strategic Position & Investments
Heron’s strategic direction emphasizes expanding the adoption of its acute care portfolio within hospital settings and broadening labeled indications for its approved products. A key growth initiative is increasing utilization of ZYNRELEF in a wider range of surgical procedures as part of multimodal, opioid‑sparing pain management protocols. The company is also focused on driving formulary access and clinical adoption of APONVIE and CINVANTI in perioperative and oncology settings.
Investment activity has been concentrated on internal clinical development, lifecycle management, and commercial infrastructure rather than large external acquisitions. Heron has periodically invested in post‑approval clinical studies and health‑economics data generation to support reimbursement and guideline inclusion. Based on available public filings, the company does not maintain a diversified portfolio of equity investments or independently operating subsidiaries; its strategy remains centered on maximizing the value of its existing commercial products and proprietary formulation technologies.
Geographic Footprint
Heron Therapeutics is headquartered in San Diego, California, and its primary operational, commercial, and administrative activities are based in the United States. The company’s revenue is predominantly generated from U.S. sales, reflecting its focus on FDA‑approved products marketed to domestic hospitals and surgical centers.
Internationally, Heron has limited direct operational presence. Distribution outside the United States has historically occurred through licensing or supply arrangements in select markets, but public disclosures indicate that international sales are not currently a significant contributor to overall revenue. The company’s global influence is therefore primarily indirect, through regulatory approvals and product use in non‑U.S. markets supported by partners.
Leadership & Governance
Heron Therapeutics is led by an executive team with experience in hospital‑based pharmaceuticals, oncology supportive care, and specialty drug commercialization. The leadership team emphasizes disciplined capital allocation, commercial execution in acute care settings, and lifecycle expansion of approved assets.
Key executives include:
- Craig A. Collard – Chief Executive Officer
- Bob Ranguelov – Chief Financial Officer
- Mark B. Kaye, MD – Chief Medical Officer
- Kevin C. Tang – Chief Commercial Officer
The company is governed by a board of directors with backgrounds in biopharmaceutical development, finance, and healthcare operations, providing oversight aligned with Heron’s strategy of focused growth within acute care therapeutics.